Central angiotensin II-induced pressor responses and neural activity in utero and hypothalamic angiotensin receptors in preterm ovine fetus.
The central renin-angiotensin system is important in the control of blood pressure in the adult. However, few data exist about the in utero development of central angiotensin-mediated pressor responses. Our recent studies have shown that the application of ANG II into the fetal brain can increase blood pressure at near term. The present study determined fetal blood pressure and heart rate in response to a central application of ANG II in the chronically prepared preterm ovine fetus, determined the action sites marked by c-Fos expression in the fetal central pathways after intracerebroventricular injection of ANG II in utero, and determined angiotensin subtype 1 receptors in the fetal hypothalamus. Central injection of ANG II significantly increased fetal mean arterial pressure (MAP). Adjusted fetal MAP against amniotic pressure was also increased by ANG II. Fetal heart rate was subsequently decreased after the central administration of ANG II and/or the increase of blood pressure. ANG II induced c-Fos expression in the central putative cardiovascular area, the paraventricular nuclei in the brain sympathetic pathway. Application of ANG II also caused intense Fos immunoreactivity in the tractus solitarius nuclei in the hindbrain. In addition, intense angiotensin subtype 1 receptors were expressed in the hypothalamus at preterm. These data demonstrate that central ANG II-related pressor centers start to function as early as at preterm and suggest that the central angiotensin-related sympathetic pathway is likely intact in the control of blood pressure in utero.
Xu
Zhice
Z
Harbor-University of California Los Angeles Medical Center, (UCLA), Harbor-UCLA Medical Center, Torrance, CA 90502, USA. zxu@gcrc.rei.edu
Shi
Lijun
L
Yao
Jiaming
J
D000804:Angiotensin II / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D005333:Fetus / Q000502:physiology*; D016762:Genes, fos / Q000235:genetics; D006340:Heart Rate, Fetal / Q000187:drug effects; D006439:Hemodynamics / Q000502:physiology; D007031:Hypothalamus / Q000187:drug effects*; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D009434:Neural Pathways / Q000196:embryology / Q000502:physiology; D009474:Neurons / Q000187:drug effects*; D011247:Pregnancy; D011945:Receptors, Angiotensin / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000502:physiology; D012756:Sheep; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology*
D011945:Receptors, Angiotensin; D014662:Vasoconstrictor Agents; D000804:Angiotensin II